There is increasing interest in the role played by the cysteinyl leukotrienes in the pathogenesis of bronchial asthma. They have been demonstrated to have a bronchoconstrictor effect both in vitro and in vivo and have been isolated from bronchoalveolar lavage fluid and urine from stable asthmatics and from asthmatics during exacerbations and after endobronchial challenge. Pharmacological intervention has been studied through antagonism of leukotriene receptors and inhibition of leukotriene synthesis. Both have been shown to have an effect on the asthmatic response after challenge with allergen, exercise and inhalation of cold air and to have an effect on aspirin sensitive asthmatics and on the symptoms and markers of severity of chronic asthma. The differences between receptor antagonism and synthesis inhibition are discussed.
INTRODUCTION
There is increasing evidence for the role played by the cysteinyl leukotrienes LTC4, LTD4 and LTE4 in the pathogenesis of bronchial asthma. Evidence is also accumulating that pharmacological manipulation through antagonism or inhibition of their synthesis might be clinically useful in the treatment of asthma.
The cysteinyl leukotrienes are generated by the enzyme 5lipoxygenase (5LO; Fig. 1 ) which acts on arachidonic acid in conjunction with 5LO associated protein (FLAP) to generate the unstable epoxide LTA4. This is then either converted to LTB4 or, via LTC4 synthase, to the cysteinyl leukotriene LTC4 which is subsequently converted by y-glutamyltranspeptidase to LTD4 and by a dipeptidase to LTE4.
BRONCHOCONSTRICTOR EFFECT OF THE LEUKOTRIENES
In vitro studies with LTC4 have demonstrated a contractile action on isolated human bronchus2 and tracheal smooth muscle3 with a potency of 1000 times that of histamine. Isolated human bronchi of diameter 3-12mm have a high degree of baseline bronchomotor tone equivalent to 50% of maximal bronchoconstriction induced by. BaCI2. This resting tone is reduced by preincubation with the LTD4 antagonists ICI 204,219 and SKF 104,353 and this reduction is additive to that induced by the addition of histamine Hl antagonists suggesting thatthis resting tone is mediated by the continuous production of histamine and leukotrienes .4 In vivo studies have revealed a bronchoconstrictor effect of inhaled nebulized solutions of leukotrienes in both normal and asthmatic individuals. In normal subjects, LTC4 is 600-9500 times as potent as histamine in causing a 30% fall in expiratory flow at a lung volume of 30% of baseline vital capacity above residual volume.5 LTD4 was found to be 6000 times more potent than histamine.b LTE4 appears to be only 40-60 times as potent as histamine but has a longer duration of action when compared to the other cysteinyl leukotrienes. 7, 8 In asthmatic individuals the leukotrienes also have a bronchoconstrictor effect. However, in asthmatics LTC4 is only 40 times as potent as histamine in inducing bronchoconstriction9 and LTD4 only 140 times as potent.10 Further studies have confirmed that the relative (to histamine) potencies of LTC4 and LTD4 are reduced in asthmatics when compared to nonasthmatics.11
A further study has shown that when compared to normal individuals, asthmatics have a 14-fold greater response to histamine, a 15-fold greater response to methacholine, a 6-fold greater response to LTC4, a 9-fold greater response to LTD4, and a 219 times greater response to LTE4. Furthermore, as airways became more hyperresponsive as judged by their response to histamine and methacholine, so the relative potency of LTE4 increases when compared to LTC4 and LTD4.12
Aspirin-sensitive asthma
Studies in asthmatics whose asthma is precipitated by aspirin have shown that these individuals are exquisitely sensitive to LTE4. In aspirin-sensitive asthmatics LTE4 is 1870 times more potent than histamine in inducing bronchospasm whereas in non-aspirin-sensitive asthmatics, LTE4 is only 145 times as potent as histamine.13 Furthermore, desensitization of these patients to aspirin leads to a fall in the relative potency of LTE4 by 20-fold, suggesting that LTE4 plays a part in the induction of bronchospasm in this group. This hyperresponsiveness is specific to LTE4 and is not seen with LTC4.14 These studies suggest that LTC4 and LTD4 appear to have less relative potency in asthmatics when compared to normal individuals but that asthmatic airways, and especially those of 16 Drazen et al. looked at 72 patients attending accident and emergency departments with asthma and found that urinary LTE4 levels were higher in those who responded to a nebulized bronchodilator when compared to those who did not, suggesting that cysteinyl leukotrienes may have a bronchospastic role in acute asthma.17
ENDOBRONCHIAL CHALLENGE
Wenzel et al. investigated a group of atopic asthmatics with endobronchial allergen challenge and found that LTC4 was the predominant leukotriene and increased 9-fold after challenge. 18 In addition, whereas LTC4 was detected in 9 of 11 atopic asthmatics at baseline, it was detected in only one out of seven atopic non-asthmatics and one out of six non-atopics. A further study by the same group19 measured levels of the mast cell derived products PGD2, TXB2, LTC4 and histamine before and 5 min after endobronchial allergen challenge in seven nonasthmatics, six asthmatics and six asthmatics with a late asthmatic response (LAR), all of whom were atopic. 19 Detectable levels of LTC4 were found in 9 out of 12 of the asthmatics and in only one out of seven of the non-asthmatics. An increase in all four mediators after challenge was found in the asthmatics only. In addition, the asthmatic group without a LAR had a greater increase in mediator levels when compared with asthmatics with a LAR. In a study of allergen provocation sufficient to cause 25-59% fall in FEV, (forced expiratory volume in one second) in 17 allergic asthmatics, urinary LTE4 levels were found to increase from 46 to 92ng/24h. No increase in urinary LTE4 was detected after methacholine challenge caused a similar fall in FEV,. Whereas a correlation existed between urinary LTE4 and the decrease in FEY, in the early asthmatic response (EAR), there was no correlation with the fall in FEV1, in the LAR. 20 Manning et al. looked at 18 asthmatics and found an increase in urinary LTE4 in those with an early asthmatic response and that the degree of bronchoconstriction correlated with the level of urinary LTE4.21 Those with a dual asthmatic response had a lesser but still significant increase in urinary LTE4 and those with an isolated LAR had no increase. Cysteinyl leukotrienes, therefore, appear to be important in the EAR and contribute significantly to the degree of bronchoconstriction. 
LEUKOTRIENE ANTAGONISTS
The evidence for the role of the cysteinyl leukotrienes in asthma has been supported by studies involving both leukotriene antagonists and agents which inhibit their synthesis. Several studies suggest that a number of LTD4 antagonists developed for use in human trials have a blunting effect on the fall in FEV1 seen in asthmatics when experimentally challenged with allergen, exercise, inhalation of cold dry air and aspirin. The first generation antagonists LY 171,883 and LY 649,923 produce a slight fall in the EAR after allergen challenge but have no effect on baseline FEV, or the LAR.23,24 Ten asthmatics pretreated with the selective and potent second generation oral agent ICI 204,219 showed a reduction of 80% in their EAR and of 50% in their LAR (Fig. 2 ).25 Treatment also suppressed an increase in bronchial reactivity 6h post challenge. Inhaled ICI 204,219 was not as effective and although it reduced the EAR, it had no effect on the LAR. 26 In addition, a single dose of inhaled ICI 204,219 produced a 10-fold rightward shift in the dose response curve to inhaled cat allergen.27 Inhaled ICI 204,219 also led to a shortening of the recovery time of the EAR from 60 to 40 min. 28 The quinolone derivative MK571 has also been shown to inhibit the EAR by 88% and the LAR by 63%.29
Studies in exercise-induced asthma have shown that SK & F 104,353, a weak LTD4 antagonist, led to a reduction from 29 to 20% in the exercise-induced bronchoconstrictor response, this being of a similar degree to that seen with sodium cromoglycate.30 In a model for exercise-induced asthma, oral treatment with ICI 204,219 resulted in a reduction in the fall in FEV1 after inhalation of cold dry air from 36 to 21% in eight asthmatics. 33 A further study on the same compound revealed a halving of the fall in FEV1 after exercise in nine asthmatics.32 MK571 also led to a decrease in the fall in FEV1 and a shortening in the recovery time from 33 to 8 min in 12 asthmatics after exercise ( Fig. 3) 33 However, despite their potency, LTD4 antagonists were unable to abolish the bronchospastic response to exercise completely, suggesting that other mediators such as mast cell histamine and prostaglandins are important in this reaction.
Aspirin-sensitive asthma is probably the most leukotriene- being inversely proportional to the baseline FEV1 and additive to that produced by albuterol ( Fig. 4 ).38 MK679 also led to an 18% increase in FEV1 in eight aspirin-sensitive asthmatics with the degree of bronchodilation again strongly correlating with the severity of asthma39 suggesting that cysteinyl leukotrienes play a major role in determining resting tone. Treatment with MK476 led to a 12% increase in FEY, in a group of moderate asthmatics.40 Addition of the LTD4 antagonist RG 12525 to existing steroid treatment led to an increase in FEV1 in stable asthmatic subjects.41
Chronic asthma
The LTD4 antagonists also appear to provide symptomatic benefit in chronic asthma. Treatment with oral LY 171,883 for 6 weeks in a group of 138 asthmatics led to an increase in FEV1 from 73.8 to 83.3% of that predicted by age and height, an improvement in symptoms of wheeze and dyspnea and a chest tightness.42 Oral MK571 treatment for 6 weeks led to an 8-14% increase in FEV, and a 30% reduction in salbutamol usage.43 Six weeks of oral ICI 204,219 in mild to moderate asthma led to an improvement in their daytime asthma score, nocturnal awakenings and morning peak flow recordings.39 A study of varying doses of the antagonist ICI 204,219 in 266 moderate asthmatics found a reduction in nocturnal awakening (by 46%), a decrease in first morning asthma symptoms, daytime asthma scores (by 26%) and salbutamol use (by 30%), and an increase in FEV1 (by 11%) and evening peak expiratory flow rates (PEFR). 44 
5-LIPOXYGENASE (5LO) INHIBITORS
There are a number of theoretical arguments to suggest that an inhibition of 5LO would be more effective than antagonism of a specific leukotriene receptor. First, inhibition of 5LO leads to a reduction in not only the cysteinyl leukotrienes LTC4, LTD4 and LTE4, but also LTB4. 45 In addition, there is evidence that leukotriene receptor antagonism alone may prolong the half lives of some of the leukotrienes by interfering with their elimination, thereby possibly potentiating their action.36 Studies on the 5LO inhibitors have addressed their effect on the asthmatic response to challenge with allergen, cold air, exercise and aspirin.
In a study of nine asthmatics, the 5LO inhibitor, zileuton, led to complete inhibition of ex vivo whole blood LTB4 generation and a reduction of 50% in the rise of urinary LTE4 post-allergen challenge. However, there was no reduction in the EAR or LAR and no reduction in airway responsiveness post-challenge.47
The potent and selective inhibitor ZD2138 led to an 82% fall in ex vivo whole blood LTB4 generation and a 72% decrease in the rise in urinary LTE4 but again had no effect on the EAR or the LAR.48 A study of eight atopic men wtih the translocation Administration of the FLAP inhibitor MK0591 prior to allergen challenge led to a 96% inhibition of LTB4 and an 84% inhibition of urinary LTE4 production 24 h post-allergen challenge.
In addition, there was a fall of 79% in the EAR and the LAR was delayed by 3 h.50 BAYx1005, a FLAP inhibitor of similar potency to MK0591, was administered to atopic asthmatics and led to a reduction of 68% in the EAR to inhaled allergen and an 87% reduction in urinary LTE4.51
Thirteen asthmatics premedicated with a single dose of zileuton had a reduction in ex vivo LTB4 generation of 74% and an increase of 47% in the amount of cold air required to cause a fall in FEV, of 10%.52 Twenty-four asthmatics treated wtih a 2 day course of zileuton had a 40% fall in the amount of exercise induced bronchospasm. 53 Treatment with zileuton in eight aspirin-sensitive asthmatics led to a fall in urinary LTE4 of 70% and prevented a drop in FEV1 after aspirin challenge. 54 Similarly, ZD2138 protects against aspirin-induced asthma with a 20.3% fall after challenge and treatment with placebo, and a fall of 4.9% after treatment with ZD2138 was associated with a reduction in whole blood LTB4 generation of 72% and of urinary LTE4 of 74% at 6 h For 4 weeks, 109 asthmatics with baseline FEV1 ranging from 50 to 75% of predicted were treated with inhaled steroids with MK0591 or placebo. The group treated with MK0591 had an increase in their FEV1 of 6.8% whereas placebo had an increase of 0.6%. Increases in morning and evening PEFR of 19 and 135% respectively, were also noted as was a decrease in 13-2 agonist use.57 CONCLUSION It appears that despite theoretical advantages over the leukotriene antagonists the 5-lipoxygenase (5LO) antagonists do not suppress leukotriene mediated processes any more than the leukotriene antagonists. This may be because, although 5LO inhibitors are effective in reducing ex vivo LTB4 generation and urinary LTE4 excretion, they are not potent enough to inhibit intra-airways Leukotriene generation and that even small amounts of leukotrienes in this area may be able to exert pathological effects. In addition, 5LO inhibition may decrease the amount of lipoxin A4 generated which may itself have a moderating effect on leukotriene action.' Similarly, inhibition of 5LO may lead to shunting of arachidonic acid derivatives down the cyclooxygenase pathway with the generation of proinflammatory products.
Further details are needed to investigate whether these compounds have steroid sparing effects and their effect on longterm symptoms. Similarly, biopsy studies to investigate the effects on airways inflammation of these compounds are needed. Finally, although there is evidence that leukotrienes are implicated in the pathogenesis of asthma and that pharmacological modification of their action has been shown to be effective in both models of acute asthma and on chronic asthma, it should be noted that leukotrienes are just one of many proinflammatory compounds active in asthma.
